AF
TVRD

Amalgamated Financial’s Tvardi Therapeutics TVRD Stock Holding History

Amalgamated Financial’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$232K Buy
+530
New +$218K ﹤0.01% 1845

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Amalgamated Financial's TVRD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Tvardi Therapeutics (TVRD) in Q1 2022: 530 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #1845 among its holdings.

183 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Amalgamated Financial held 530 shares of Tvardi Therapeutics worth $232K as of Q1 2022.
  • Tvardi Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Tvardi Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1845 holding.
  • 183 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.